As Labcorp has grown through acquisitions like PGDx, Invitae, and BioReference's oncology business, and through 130+ new tests in 2025, each addition has brought new instruments and new data paths. Steve Ragan (Labcorp) and Hinel Karia (AWS) discuss how a national lab network decides where its sequencing data should go, and what other labs can learn from it.